Dyne Therapeutics (DYN) Competitors $8.17 +0.34 (+4.34%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$8.27 +0.10 (+1.27%) As of 04/17/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN vs. PTCT, OGN, ZLAB, ACLX, RNA, RARE, AKRO, MOR, SWTX, and PTGXShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include PTC Therapeutics (PTCT), Organon & Co. (OGN), Zai Lab (ZLAB), Arcellx (ACLX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. PTC Therapeutics Organon & Co. Zai Lab Arcellx Avidity Biosciences Ultragenyx Pharmaceutical Akero Therapeutics MorphoSys SpringWorks Therapeutics Protagonist Therapeutics PTC Therapeutics (NASDAQ:PTCT) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings. Is PTCT or DYN more profitable? Dyne Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics-50.32% N/A -16.44% Dyne Therapeutics N/A -57.46%-51.62% Which has better valuation & earnings, PTCT or DYN? Dyne Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M4.63-$626.60M-$4.73-10.02Dyne TherapeuticsN/AN/A-$235.94M-$3.35-2.44 Does the MarketBeat Community prefer PTCT or DYN? PTC Therapeutics received 525 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 77.19% of users gave Dyne Therapeutics an outperform vote while only 61.92% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformPTC TherapeuticsOutperform Votes56961.92% Underperform Votes35038.08% Dyne TherapeuticsOutperform Votes4477.19% Underperform Votes1322.81% Do institutionals and insiders believe in PTCT or DYN? 96.7% of Dyne Therapeutics shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate PTCT or DYN? PTC Therapeutics currently has a consensus price target of $63.77, indicating a potential upside of 34.56%. Dyne Therapeutics has a consensus price target of $47.46, indicating a potential upside of 480.92%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 2 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07 Which has more risk and volatility, PTCT or DYN? PTC Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Does the media refer more to PTCT or DYN? In the previous week, Dyne Therapeutics had 2 more articles in the media than PTC Therapeutics. MarketBeat recorded 8 mentions for Dyne Therapeutics and 6 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.68 beat Dyne Therapeutics' score of 0.47 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDyne Therapeutics beats PTC Therapeutics on 13 of the 18 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$924.20M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-2.296.8921.8017.78Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book5.485.916.443.97Net Income-$235.94M$142.72M$3.21B$247.65M7 Day Performance16.05%4.38%2.85%1.80%1 Month Performance-35.06%-12.76%-8.64%-6.98%1 Year Performance-65.45%-9.69%11.38%1.34% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.5443 of 5 stars$8.17+4.3%$47.46+480.9%-67.1%$924.20MN/A-2.29100PTCTPTC Therapeutics3.7608 of 5 stars$42.82-1.0%$63.77+48.9%+88.4%$3.38B$806.78M-7.211,410Upcoming EarningsShort Interest ↑News CoverageOGNOrganon & Co.4.793 of 5 stars$12.54-3.9%$20.80+65.9%-37.8%$3.23B$6.40B3.7610,000Short Interest ↓ZLABZai Lab2.8615 of 5 stars$28.81-9.3%$47.37+64.4%+110.2%$3.16B$398.99M-10.401,950Gap UpHigh Trading VolumeACLXArcellx2.0628 of 5 stars$56.65-3.3%$110.67+95.4%+15.8%$3.11B$107.94M-79.7980Positive NewsHigh Trading VolumeRNAAvidity Biosciences2.1627 of 5 stars$25.48-4.1%$66.69+161.7%+13.2%$3.06B$10.90M-8.85190RAREUltragenyx Pharmaceutical4.5444 of 5 stars$32.14-0.9%$92.79+188.7%-19.1%$3.02B$560.23M-5.071,310Analyst RevisionPositive NewsAKROAkero Therapeutics4.2749 of 5 stars$35.97-2.1%$76.29+112.1%+74.2%$2.86BN/A-9.5930Insider TradeGap DownHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics2.2358 of 5 stars$36.99-5.4%$73.20+97.9%-14.1%$2.77B$191.59M-10.63230Options VolumeNews CoverageHigh Trading VolumePTGXProtagonist Therapeutics3.7942 of 5 stars$43.21-2.8%$62.56+44.8%+81.0%$2.65B$434.43M16.24120News CoveragePositive News Related Companies and Tools Related Companies PTC Therapeutics Competitors Organon & Co. Competitors Zai Lab Competitors Arcellx Competitors Avidity Biosciences Competitors Ultragenyx Pharmaceutical Competitors Akero Therapeutics Competitors MorphoSys Competitors SpringWorks Therapeutics Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYN) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
